Methods of treating psoriasis
AssigneeMiNDERA Corporation
InventorsTobin Dickerson, Bradford Taft, Byung-In Lee
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating psoriasis. The present disclosure provides methods of using a microneedle device in aid of treating a subject. The present disclosure also provides methods of treating a subject with psoriasis with a microneedle device. The present disclosure provides microneedle devices and kits for extracting biomarkers from a tissue. The present disclosure provides methods selecting a treatment for an autoimmune disease. The present disclosure also provides methods of nucleic acid analysis to prospectively predict a patient's response to a therapeutic.
Claims19
A method of treating a human subject with psoriasis, comprising:
- (a) obtaining RNA molecules from a lesional skin of the human subject with psoriasis by applying a microneedle device to the lesional skin of the human subject, wherein the microneedle device comprises one or more nucleic acids probes that are capable of hybridizing to the RNA molecules, wherein the human subject has not been administered an IL-23 inhibitor prior to the obtaining the RNA molecules;
- (b) assaying the obtained RNA molecules in order to identify expression levels of MTCO1P12, MTATP6P1, CLSTN1, PDPN, LDLRAD2, AL158847.1, GSTM3, CRCT1, LCE6A, ITM2C, CRTAP, UCN2, TP63, EREG, GLRX, NREP, FCHSD1, DST, HOXA9, LAMB1, MXRA5, ZNF395, SNAI2, NPR2, SPAG8, GPSM1, TP53111, PACSIN3, TYR, USP2, PPIF, AGAP11, AL136982.1, AL136982.4, AL136982.2, AL136982.5, MGMT, HOXC6, PRIM1, LLPH, HAL, TXNRD1, AC089983.1, EID3, RNASE7, DAD1, JAG2, KIFC3, SMPD3, and PLCD3, by sequencing the obtained RNA molecules;
- (c) predicting that the human subject with psoriasis will be responsive to the IL-23 inhibitor based on the expression levels in (b);
- and
- (d) based on (c), administering the IL-23 inhibitor to the human subject.
Dependencies are inferred from the claim text.